NetworkNewsBreaks – Phivida Holdings Inc. (CSE:
Post# of 29
(Total Views: 212)
Posted On: 10/02/2018 5:58:06 PM
NetworkNewsBreaks – Phivida Holdings Inc. (CSE: VIDA) (OTCQX: PHVAF) Issues Response to DEA Rescheduling of CBD
Phivida Holdings Inc. (CSE: VIDA) (OTCQX: PHVAF), a premium functional food and beverage company, this morning issued a response to the U.S. Drug Enforcement Administration’s recent decision to remove cannabis component cannabidiol from its Schedule I list of controlled substances. “We see this reclassification of CBD in pharmaceuticals as a good sign that will bolster the growing awareness of CBD as a substance that delivers many benefits, and opens the door for other CBD-based treatments, in line with the recent FDA approval of a drug to treat childhood epilepsy,” Jim Bailey, president and CEO of Phivida, stated in the news release. “Phivida is launching its Oki line of functional beverages which provide a spectrum of non-psychoactive phytocannabinoids through infusion with active hemp extract. While our Oki and Vida+ product lines are not subject to FDA approval, as we grow to have product on shelves in all 50 states, we will benefit from the increased acceptance of the efficacy of cannabis and hemp products.” Phivida additionally announced the issuance of roughly 1.5 million common shares to serve as payment for a combination of consulting services provided in regards to an advisory on the Cannabis Beverages Inc. (“CanBev”) joint venture with WeedMD Inc. and management sourcing.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Phivida Holdings Inc. (CSE: VIDA) (OTCQX: PHVAF), a premium functional food and beverage company, this morning issued a response to the U.S. Drug Enforcement Administration’s recent decision to remove cannabis component cannabidiol from its Schedule I list of controlled substances. “We see this reclassification of CBD in pharmaceuticals as a good sign that will bolster the growing awareness of CBD as a substance that delivers many benefits, and opens the door for other CBD-based treatments, in line with the recent FDA approval of a drug to treat childhood epilepsy,” Jim Bailey, president and CEO of Phivida, stated in the news release. “Phivida is launching its Oki line of functional beverages which provide a spectrum of non-psychoactive phytocannabinoids through infusion with active hemp extract. While our Oki and Vida+ product lines are not subject to FDA approval, as we grow to have product on shelves in all 50 states, we will benefit from the increased acceptance of the efficacy of cannabis and hemp products.” Phivida additionally announced the issuance of roughly 1.5 million common shares to serve as payment for a combination of consulting services provided in regards to an advisory on the Cannabis Beverages Inc. (“CanBev”) joint venture with WeedMD Inc. and management sourcing.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)